Top Breast Cancer News of 2016

Slideshow

This slide show highlights some of the top breast cancer news of 2016, including a study looking at optimal margins in DCIS, a trial on biosimilars, a new FDA approval, and more.

Recent Videos
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Related Content
T-DXd demonstrated a safety profile consistent with previously reported analyses.

T-DXd Improves Invasive DFS vs T-DM1 in HER2+ Early Breast Cancer Subgroup

Tim Cortese
September 29th 2025
Article

Planned interim results from the phase 3 DESTINY-Breast05 trial showed no new safety signals with T-DXd in the trial population.

Upfront risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Cardiovascular Considerations in Breast Cancer Treatment and Survivorship

Joseph S. Wallins, MD, MPH
September 8th 2025
Podcast

Up-front risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Though overall survival (OS) was at approximately 16% maturity at data cutoff, a favorable trend for the T-DXd regimen has been observed.

The FDA Grants Priority Review to T-DXd/Pertuzumab in 1L Metastatic Breast Cancer

Tim Cortese
September 24th 2025
Article

Results from the phase 3 DESTINY-Breast09 trial will support the FDA’s decision on whether to approve T-DXd plus pertuzumab in frontline metastatic breast cancer.

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Data from the phase 3 evERA trial show a trend towards improved overall survival with giredestrant plus everolimus in this breast cancer population.

Giredestrant Combo Significantly Boosts PFS in ER+ Advanced Breast Cancer

Russ Conroy
September 22nd 2025
Article

Data from the phase 3 evERA trial show a trend toward improved overall survival with giredestrant plus everolimus in this breast cancer population.

ProSense® is a minimally invasive treatment option that destroys tumors by freezing them, utilizing liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction.

ProSense Cryoablation Satisfies Patients With Breast Cancer vs Alternatives

Tim Cortese
September 9th 2025
Article

THERMAC trial results revealed that the ProSense® cryoablation system showed no complications, and the highest complete ablation rate in breast cancer.